Irish firm Elan Corp achieved a 66% increase in net income to IRL18.0 million ($28.3 million) for the quarter ended March 31, 1996. Earnings per share were 44 Irish pence. Revenues for the quarter were IRL47.1 million, up 58%. For the full year, net income was IRL56.4 million, up 35%, EPS were IRL1.51, rising 29.5%. There was a 19% increase in total revenues for the year to IRL141.7 million.
Product sales, which included turnover from contract manufacturing activities for client companies and sales of Elan-marketed products, grew 82% to IRL25.7 million in the fourth quarter. This was attributed to shipments of Elan's once-daily naproxen product Naprelan to Wyeth-Ayerst, the firm's US marketing partner, Herbesser (diltiazem) shipments to Japanese partner Tanabe Seiyaku, and sales of Theodur Sprinkle to Mitsubishi Kasei, also in Japan.
Fourth-quarter R&D expenditure was IRL7.1 million, up 42% on last year.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze